Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PML_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PML_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PML_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PML_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PML_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0097191110 | Oral cavity | LP | extrinsic apoptotic signaling pathway | 91/4623 | 219/18723 | 2.69e-08 | 9.80e-07 | 91 |
GO:0072331110 | Oral cavity | LP | signal transduction by p53 class mediator | 72/4623 | 163/18723 | 3.99e-08 | 1.41e-06 | 72 |
GO:000734614 | Oral cavity | LP | regulation of mitotic cell cycle | 163/4623 | 457/18723 | 7.64e-08 | 2.56e-06 | 163 |
GO:001907613 | Oral cavity | LP | viral release from host cell | 23/4623 | 34/18723 | 1.54e-07 | 4.84e-06 | 23 |
GO:003589013 | Oral cavity | LP | exit from host | 23/4623 | 34/18723 | 1.54e-07 | 4.84e-06 | 23 |
GO:003589113 | Oral cavity | LP | exit from host cell | 23/4623 | 34/18723 | 1.54e-07 | 4.84e-06 | 23 |
GO:0034599110 | Oral cavity | LP | cellular response to oxidative stress | 110/4623 | 288/18723 | 2.19e-07 | 6.65e-06 | 110 |
GO:000072317 | Oral cavity | LP | telomere maintenance | 59/4623 | 131/18723 | 2.88e-07 | 8.56e-06 | 59 |
GO:000756819 | Oral cavity | LP | aging | 125/4623 | 339/18723 | 3.29e-07 | 9.62e-06 | 125 |
GO:001820513 | Oral cavity | LP | peptidyl-lysine modification | 136/4623 | 376/18723 | 3.64e-07 | 1.06e-05 | 136 |
GO:004477215 | Oral cavity | LP | mitotic cell cycle phase transition | 150/4623 | 424/18723 | 4.38e-07 | 1.23e-05 | 150 |
GO:0072332110 | Oral cavity | LP | intrinsic apoptotic signaling pathway by p53 class mediator | 39/4623 | 76/18723 | 5.10e-07 | 1.40e-05 | 39 |
GO:001021216 | Oral cavity | LP | response to ionizing radiation | 64/4623 | 148/18723 | 5.60e-07 | 1.51e-05 | 64 |
GO:200105619 | Oral cavity | LP | positive regulation of cysteine-type endopeptidase activity | 64/4623 | 148/18723 | 5.60e-07 | 1.51e-05 | 64 |
GO:0045185110 | Oral cavity | LP | maintenance of protein location | 45/4623 | 94/18723 | 9.06e-07 | 2.33e-05 | 45 |
GO:0043903110 | Oral cavity | LP | regulation of biological process involved in symbiotic interaction | 37/4623 | 72/18723 | 9.49e-07 | 2.43e-05 | 37 |
GO:004328019 | Oral cavity | LP | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 57/4623 | 129/18723 | 9.81e-07 | 2.48e-05 | 57 |
GO:0042177110 | Oral cavity | LP | negative regulation of protein catabolic process | 54/4623 | 121/18723 | 1.28e-06 | 3.13e-05 | 54 |
GO:003250718 | Oral cavity | LP | maintenance of protein location in cell | 34/4623 | 65/18723 | 1.53e-06 | 3.65e-05 | 34 |
GO:007259516 | Oral cavity | LP | maintenance of protein localization in organelle | 25/4623 | 42/18723 | 1.64e-06 | 3.85e-05 | 25 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PML | SNV | Missense_Mutation | novel | c.1022C>T | p.Ser341Leu | p.S341L | P29590 | protein_coding | deleterious(0.03) | probably_damaging(0.983) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PML | SNV | Missense_Mutation | | c.1228N>G | p.Pro410Ala | p.P410A | P29590 | protein_coding | tolerated(0.06) | probably_damaging(0.95) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
PML | deletion | Frame_Shift_Del | | c.208delN | p.Leu70CysfsTer28 | p.L70Cfs*28 | P29590 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
PML | SNV | Missense_Mutation | rs769540520 | c.2221N>T | p.Arg741Cys | p.R741C | P29590 | protein_coding | deleterious(0.03) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PML | SNV | Missense_Mutation | rs765869727 | c.973C>T | p.Arg325Cys | p.R325C | P29590 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A1M5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
PML | SNV | Missense_Mutation | | c.895G>C | p.Glu299Gln | p.E299Q | P29590 | protein_coding | tolerated(0.23) | benign(0.3) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
PML | SNV | Missense_Mutation | | c.1702N>A | p.Glu568Lys | p.E568K | P29590 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-EA-A97N-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PML | SNV | Missense_Mutation | | c.502N>A | p.Glu168Lys | p.E168K | P29590 | protein_coding | deleterious(0) | possibly_damaging(0.606) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
PML | SNV | Missense_Mutation | novel | c.1015N>A | p.Tyr339Asn | p.Y339N | P29590 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-MA-AA43-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
PML | SNV | Missense_Mutation | rs745678082 | c.2218N>A | p.Glu740Lys | p.E740K | P29590 | protein_coding | tolerated(0.2) | benign(0.007) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5371 | PML | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | GEMTUZUMAB OZOGAMICIN | | 15187030 |
5371 | PML | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | TRETINOIN | TRETINOIN | 21505136,8674046,21613260,23670176,11704842,30289902 |
5371 | PML | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | arsenic trioxide | | 24433361 |
5371 | PML | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | tretinoin | TRETINOIN | |
5371 | PML | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | TAMIBAROTENE | TAMIBAROTENE | 30289902 |
5371 | PML | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | TAZAROTENE | TAZAROTENE | 16939905 |
5371 | PML | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | Tretinoin | TRETINOIN | |
5371 | PML | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | ARSENIC TRIOXIDE | | 26537301,11704842 |